Cluster 2 was identified as a significantly favorable independent predictor for PFS, along with younger age and methylated MGMT. Expression profiling using RNA sequencing identified that Cluster 2, which was enriched with the genes involved in macrophage or microglia activation, was associated with longer OS and PFS independent of the MGMT methylation status. The primary endpoint, the 2-year survival rate of the BBP group, was 27.0% and was unmet. In the BBP group, in which O 6-methylguanine-DNA methyltransferase ( MGMT)-unmethylated tumors predominated, mOS and mPFS were 5.8 and 1.9 months from BBP initiation and 16.8 and 11.4 months from the initial diagnosis, respectively. Median overall survival (mOS) and median progression-free survival (mPFS) were 25.0 and 14.9 months, respectively.

Ninety patients received the protocol-defined primary therapy (BBP group, n = 25).

This phase II study evaluated a protocol-defined primary therapy by radiotherapy with concurrent and adjuvant temozolomide plus bevacizumab, followed by bevacizumab monotherapy, and secondary therapy (BBP: bevacizumab upon progression). We evaluated the efficacy and safety of bevacizumab beyond progression (BBP) in Japanese patients with newly diagnosed glioblastoma and explored predictors of response to bevacizumab.

Call to arms d2 base